Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Aqua Bio Technology Board/Management Information 2020

Sep 11, 2020

3535_dirs_2020-09-11_a6de2a73-2992-4871-8e0b-518cd26bf0ed.html

Board/Management Information

Open in viewer

Opens in your device viewer

Aqua Bio Technology Asa - Primary Insider Notification

Aqua Bio Technology Asa - Primary Insider Notification

Reference is made to the stock exchange notice from Aqua Bio Technology ASA (the

"Company") on 11 September 2020 regarding the result of a subsequent offering

(the "Subsequent Offering"). In the Subsequent Offering, investors who

participated in the private placements announced on 17 and 18 August 2020 was

granted a right to subscribe for shares that were subscribed pursuant to

subscription rights in the Subsequent Offering.

Reference is furthermore made to the minutes from the general meeting held

earlier today, 11 September 2020, where certain members of the Company's board

of directors and management were granted options. Further information on the

option grant is available in the minutes of the general meeting.

The following primary insiders have subscribed for shares in the Subsequent

Offering:

* Edvard Cock, chairman, has through his controlled company Blixen Invest AS

subscribed for 22,647 shares in the Subsequent Offering. Following

completion of the Subsequent Offering, Edvard Cock and related parties will

hold 1,280,793 shares in the Company and 499,998 share options.

* Roger Hofseth, director, has through his controlled company Finnvik Eiendom

AS subscribed for 64,758 shares in the Subsequent Offering. Following

completion of the Subsequent Offering, Roger Hofseth and related parties

will hold 4,014,904 shares in the Company.

* Jan Petterson, director, has through his controlled company Swelandia

International AB subscribed for 57,739 shares in the Subsequent Offering.

Following completion of the Subsequent Offering, Jan Petterson and related

parties will hold 3,960,885 shares in the Company.

* Tone Bjørnov, director, has subscribed for 8,773 shares in the Subsequent

Offering. Following completion of the Subsequent Offering, Tone Bjørnov will

hold 128,203 shares in the Company and 75,000 share options.

* Espen Dahl, related party to director Kristin Aase, has through his

controlled company Kjeveortoped Espen Dahl AS subscribed for 22,647 shares

in the Subsequent Offering. Following completion of the Subsequent Offering,

Espen Dahl and related parties will hold 1,714,058 shares in the Company. In

addition, Kristin Aase holds 75,000 share options.

* Espen Kvale, CEO, has through his controlled company EK Holding Invest AS

subscribe for 1,755 shares in the Subsequent Offering. Following completion

of the Subsequent Offering, Espen Kvale and related parties will hold

521,755 shares in the Company and hold 500,001 share options.

* Håvard Lindstrøm, Head of Business Development, has through his controlled

company Ice Capital AS subscribed for 26,319 shares in the Subsequent

Offering. Following completion of the Subsequent Offering, Håvard Lindstrøm

and related parties will hold 326,319 shares in the Company and hold

499,998 share options.

* Susanne Arnesen, Business Development Manager Nordic, has subscribed for

526 shares in the Subsequent Offering. Following completion of the

Subsequent Offering, Susanne Arnesen will hold 6,526 shares in the Company.

For further information, please contact CEO Espen Kvale, telephone

+47 9162 8092.

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on the Axess market of the

Oslo Stock Exchange.

This information is subject of the disclosure requirements pursuant to sections

5-12 and 4-2 of the Norwegian Securities Trading Act.